All posts by U.S. Stem Cell, Inc

Adipose Stem Cells Demonstrate Effectiveness in Repairing Decubitus Ulcers

Paper Published by USRM Chief Science Officer in Journal of Medical Cases

SUNRISE, FL – October 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully used autologous stem cells from fat tissue to repair decubitus ulcers.

A decubitus ulcer is a wound on the skin also known as a pressure ulcer which typically occurs over bony skin, such as buttocks.  These wounds can be common in spinal cord injury patients with limited mobility. The number of patients with pressure ulcers is estimated to be between 1.3 to 3 million in the United States.  The number of hospitalizations as a result of decubitus ulcers has increased by more than 75% between 1993 and 2006.

“We continue to identify beneficial ways to utilize our own healing stem cells retrieved from fat tissue for therapeutic use,” said Dr. Kristin Comella, USRM’s Chief Science Officer and author of the paper, “and decubitus ulcers are an important market given the aging baby boomer demographic.  The elegance and simplicity of this effective therapy cannot be overstated. It’s an incredible opportunity to utilize a patient’s own cells to repair tissue damage without the use of drugs.”

Non-healing decubitus ulcers can be challenging to treat and may often progress to other life-threatening complications.  Significant tissue damage is present in stage three/four wounds and treatment options can be limited or present additional risks.  Applications of regenerative medicine and stem cell therapy are rapidly expanding in particular in the field of non-healing wounds.  Adipose tissue is a rich source of autologous stem cells which can be easily isolated in an outpatient visit.

The paper documents a 49-year-old male with prior incomplete spinal cord injury with Stage 3 decubitus ulcer on the buttocks.  The wound had persisted for 8 months with full thickness loss of epidermis and no exposure of underlying bone, muscle or tendon.  Prior interventions include wound cleansing with hydrogen peroxide, wound dressing with Eusol (bleach, boric acid, and water) and gauze, and pressure relief by changing of position in bed.  

The patient’s autologous cells were injected directly into the ulcer.  The wound was monitored and tracked with imaging and the patient was tracked for quality of life parameters as well as safety (adverse events).  No complications or other safety events were reported either during the procedure or in the months following the procedure. The patient reported reduction of pain consistent with wound healing and a willingness to repeat therapies if required.  The healing stage 3 pressure injury showed clear re-epithelialization.

USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  

To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer Featured on YourVoice™ America

SUNRISE, FL – October 1, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, was featured on this week’s Sunday edition of YourVoiceTM Americaa fast-growing, internet broadcasting platform reaching millions of people each month.

The episode, which aired Sunday, September 30 at 8 p.m., can be viewed here.

YourVoiceTM America was founded in the wake of (weekday host) Bill Mitchell’s 90+ million Twitter hits on election night and become a strong platform for President Trump and the MAGA message.   The “Faith & Freedom” edition, hosted by successful business mogul Leigh Valentine, covers political, spiritual and lifestyle issues on Sunday nights at 8 PM EST.

“I am pleased to expand our message on multiple health and medical freedom platforms in the United States as we proactively educate lawmakers and key influencers in the Trump administration about the importance of autologous stem cell therapy,” said Comella.  “Preserving the rights of Americans to access their own healing cells must be a part of the discussion for health freedom and it was a pleasure to expand that narrative in my conversation with Leigh and the YourVoiceTM America audience.”

“Dr. Comella’s work is so important: it gives Americans the opportunity to use their own healing cells to repair damaged tissue in their bodies,” said Leigh Valentine, who is also involved nationally in faith-based strategies supporting the Trump Administration.  “Having the opportunity to provide the American people with information about this incredible healing modality is a blessing and a privilege.”

USRM has been instrumental in providing more than ten thousand stem cell procedures during the past 19 years for a variety of indications —  including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

USRM continues to sustain substantial revenue growth and has done so for two consecutive years, which may be affiliated with increasing awareness of stem cell therapy as Americans are starting to seek alternatives to pain management and opioids.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Dr. Kristin Comella Joins Top Docs in Fix for Female Hormones Seminar

SUNRISE, FL – September 26, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will be featured alongside other top doctors in the upcoming webinar summit, the Fix for Female Hormones.

Hosted by Misty Williams, the summit provides a platform for alternative and medical health professionals to weigh in on options for women seeking education and information about ways to create and establish optimal hormonal health.  Dr. Comella will present about understanding regenerative medicine; protecting telomeres and supporting healthy aging; ways to support hormones and restore sexual response, and heal exhaustion.

Dr. Comella’s segment will air for the first time on Oct. 6.  To learn more about the summit, which is free, click here, https://fixforfemalehormones.com/.  

“The way we define aging in America is changing, basically because we are waking up to the healing potential with our own bodies, and autologous stem cell therapy is a big part of that,” said Dr. Comella.  “The opportunity to help educate about regenerative therapy in the context of hormonal balance, with a panel of experts each bringing a unique perspective to the topic, is a perfect opportunity to learn more about natural approaches to this ongoing issue.”

Under Dr. Comella’s leadership, USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  

USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

CEO Blog: September 2018: An Accomplished Summer

Dear Shareholders and Friends,

Thank you for your continued interest and support in U.S. Stem Cell, Inc.’s recent developments and achievements. As we continue to grow, our main focus continues to be our mission of discovering, developing, and commercializing cell-based regenerative therapies.  As a result, we’ve had a summer full of accomplishments and events which we would like to share with you here.

First and foremost, please join us in welcoming our newest Senior Vice President of Sales, Phil Posa. Phil’s most recent role as Executive and CEO at Stem Cell Centers of Idaho, combined with his 30+ years’ extensive experience in the regenerative/medical device & pharmaceutical industries including Abbott Pharmaceuticals, make him the perfect addition to our senior management at a time when we are focused on expansion and diversification company wide. While at Stem Cell Centers of Idaho, Phil restructured patient flow which allowed the company to identify ways to improve conversion rates, service and best possible outcomes. The results helped bring sales to an all-time monthly high, resulting in a new benchmark for the company’s profitability and the launch on average of one clinic per month.  It also launched regenerative medicine into traditional insurance reimbursement medical practices, thereby converting them into ‘white glove’ concierge care cash practices.

We are certain Phil’s proven expertise and background are an incredible asset to our team, and we are looking forward to growth in our domestic and international markets under his leadership and guidance. You can read more about Phil’s background here.  

We are also delighted to announce that during the second quarter of this year we achieved the benchmark of increased revenue for our tenth consecutive quarter, up 31% from the same quarter last year from $1.39m to $1.82m. Our profit margin also increased, from 67% in the second quarter of 2017 to 69% for the second quarter of 2018.  Additionally, our gross profit rose 35% from the second quarter of 2017, increasing from $934k to $1.25m.

This has been a period of continued growth for the last two consecutive years. We believe this may be due in part to the increased awareness of stem cell therapy amongst prospect patients in the US and abroad. Furthermore, an increase in market demand can be attributed in part to patients seeking an alternative to opioids, as well as physicians looking to advance their skill sets.

In June our Chief Science Officer, Dr. Kristin Comella, presented at the Fifth Annual Cell Surgical World Conference in Beverly Hills at the Beverly Hilton Hotel.  Dr. Comella, who is well recognized for her unparalleled dedication and leadership in the development and application of clinical practices in the world of autologous stem cell therapies, presented to an audience of doctors from around the world.  Her enthusiasm was well received as many continue to admire her for her persistence, expertise and vigor in advancing the narrative of autologous stem cell therapy, and attendees at the conference were explicit and open in expressing their admiration.

On the scientific front, we recently made an exciting breakthrough in autologous stem cell therapy from fat tissue by successfully repairing the torn meniscus of a 56-year-old patient.  Meniscal injuries are recognized as the most common knee injury among Americans and without this regenerative therapy are often only repairable by surgery. According to the scientific paper by Dr. Comella published in the Journal of Medical Cases, the patient treated for chronic meniscus injury reported no adverse events in the 12 months following treatment, as well as expressing reduction in pain and an overall improvement in quality of life. Physicians confirmed a complete resolution via arthroscopic evaluation of the tear 9 months after treatment.

We are also pleased to announce we have launched participation in “Renewing our Heroes,” a charitable health initiative for civil service personnel that has been making USRM stem cell therapies and protocols accessible to first responders and those who voluntarily put their well-being on the line every day.  Firefighters, paramedics, military officials, police officers and other civil-service professionals can now have access to medical care that otherwise may have been unattainable. It is an exciting indication that we are able to reach more Americans today than have ever had access to regenerative therapy in the past, and we are delighted that those who serve us now have access to a new standard of care.

Our dedication to making regenerative medicine the new health standard continues to be unwavering. As we progress, we invite you to learn more about the aforementioned events and milestones, as well as staying up-to-date with future announcements, by reading the press releases on our news page which can be found here.

Thank you again for your interest and ongoing support.

Warmest regards,

Mike Tomas,

President and CEO

Read More

USRM Hires Senior VP of US & International Sales

USRM Hires Senior VP of US & International Sales

Former Abbott Pharmaceuticals, Stem Cell Centers Exec Joins Team

_________________________________________

SUNRISE, FL – September 11, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Phil Posa has joined its executive management team as Senior Vice President of U.S. & International Sales.

Posa, who brings more than 30 years of experience in the pharmaceutical, medical device and regenerative spaces, most recently served as an Executive and CEO at Stem Cell Centers of Idaho, where he assisted in the launch and management of new and existing clinics — at a rapid growth rate of approximately one clinic per month.

As part of the management process, Posa maintained quality control and efficiency company wide, starting with the successful negotiation of contracts with manufacturers and suppliers to provide the best possible product at the lowest possible cost.  He was also responsible for successfully designing and initiating a shift in training curriculum by emphasizing a focus on marketing, product and protocols for treatment and conditions, which resulted in the incorporation of a seamless program for patient flow thereby allowing the company to track from lead generation to patient satisfaction following treatment.

By focusing on conversion rates, service and best possible outcomes, Posa’s successful approach in design, implementation and execution helped bring sales to an all-time monthly high, resulting in a new benchmark for the company’s profitability. It also launched regenerative medicine into traditional insurance reimbursement medical practices, thereby converting them into ‘white glove’ concierge care cash practices.

“We are ecstatic to have Phil join our team, especially when we are at a pivotal point in expansion and diversification,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “The ability to assist in growing our markets both domestically and internationally is one of many skill sets Phil brings to the team. Combined with his expertise in the launch and clinical expansion in the stem cell arena, he is the perfect fit for us at this time.”    

Prior to his tenure at SCC, Posa also served as Senior Vice President U.S. & International Sales for Whale Imaging, Boston, and Skyline Medical, of Minnesota, respectively.  He received his MBA from Rivier College in New Hampshire, and a bachelor’s degree in Biology from Stony Brook University in Stony Brook, NY.  He also was certified as a Public Health Advisor by the State of New York, and as an epidemiologist by the Centers for Disease Control (CDC).

“I am very excited about the potential of U.S. Stem Cell in the U.S. and International markets, and am looking forward to building upon the world-class reputation the Company has built over the past twenty years,” said Posa.  “It is a great opportunity at just the right time in the marketplace. I am looking forward to hitting the ground running to help bring USRM to its next level of success.”

Posa also received 15 All Star awards during his tenure at Abbott Pharmaceuticals as a sales leader and manager.

USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Posts Profitable Results for Second Quarter 2018

SUNRISE, FL – August 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced results for its second quarter in 2018 — the 10th consecutive quarter where revenue has increased.

For the quarter ending June 30, 2018, the Company posted a revenue increase of 31% to $1.82m, up from $1.39m for the second quarter of last year.  Revenue also increased for the six months ended June 30, 2018, to $3.53m, up 39% from $2.54m for the same period last year.

Profit margin for the second quarter also increased, to 69% from 67% for the same period last year, and profit margin for the first six months of this year increased to 70% from 68% in the first six months of 2017.  Gross profit was also up for both periods, with a 34% increase to $1.25m from $934k for the second quarter, and a 43% increase to $2.46m from $1.73m for the six-month period.

For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Stem Cells Shows Promise For Repairing Torn Meniscus

SUNRISE, FL – July 10, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has demonstrated successful, in-human results in repairing meniscus tear after autologous stem cell therapy from adipose or fat tissue.  

Results are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.

“The ability to provide this kind of therapy to Americans can be life changing,” said Dr. Comella.  “Use of one’s own healing cells to help repair damaged tissue rather than having to cut open or manipulate the damaged area to try to reduce pain and restore function is the most elegant form of regenerative medicine we have today.”

Meniscal injuries are the most common knee injury in the United States with an annual average of incidence of 66 per 100,000, according to a 2014 article in the Journal of Orthopedics.  Approximately 850,000 patients each year are surgically treated — often arthroscopically — for meniscal injuries.  

The paper outlines the case study of a 56-year-old male with a chronic meniscus injury.  During the 12-month follow-up period, the patient reported a reduction in pain and an improvement in knee function. Figure 1a shows a tear at baseline on the posterior horn of the medial meniscus, while Figure 1b, taken 9 months after the first injection shows complete resolution of the tear. The healed tear could not be penetrated by the probe.

The arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities. The patient experienced very little downtime and was able to resume normal activities in less than 1 week.

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  USRM has been a part of more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

‘Renewing Our Heroes’ to Provide USRM Stem Cell Protocol to First Responders

SUNRISE, FL – June 5, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Renewing Our Heroes  — a charitable health initiative established to provide first responders and other civil service personnel with access to alternative medical care they would otherwise be unable to obtain — will now offer USRM stem cell procedures and protocols to its recipients following injuries and conditions that occur in the line of duty.

Established by Joseph Radich, Founder and Clinical Director of  RenewU Medical and son of an actively serving New York City firefighter, Renewing Our Heroes was created as a charitable health initiative to help individuals who voluntarily and without hesitation put their bodies, minds, families and lives on the line every day.

“I see the power of regenerative medicine, and because U.S. Stem Cell Clinic and Dr. Kristin Comella are the industry standard for holistic, autologous stem cell therapy, it only makes sense to make this protocol available to the fine men and women who serve our country,” said Radich. “Renewing Our Heroes is a way we as Americans can give back, and help them have access to what they deserve, the very best regenerative medicine has to offer.”

Dr. Kristin Comella, USRM’s Chief Science Officer, is one of the most published scientists in the world for the clinical application of autologous fat derived stem cell therapies. She is also President of the Academy of Regenerative Practices, and is a leading voice in the power of regenerative medicine.

“This is exactly why we do what we do: helping the good people of our nation find the possibility of living healthier, longer lives so that they continue to do what they do best.  For almost 20 years, I have researched, studied, tested, published and provided access to the healing, autologous stem cells in people’s bodies,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “It is a privilege to be tapping into this holistic form of stem cell therapy and to continue to serve in furthering this mission worldwide.”

“Expansion of our stem cell protocol into the line of service for our first responders means we are starting to reach more and more Americans who otherwise would never have access to this incredible regenerative therapy,” said Mike Tomas, USRM’s President and CEO.  “It is an honor for our organization to know the true heroes of our country can now have access to this standard of care.”

Dr. Comella’s leadership role inspires other organizations and physicians — 700+ clinicians and 287+ clinics worldwide — many of whom train and certify with her and the team at the U.S. Stem Cell Clinic in Sunrise, Florida.

To donate to Renewing Our Heroes, click here.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Present at Fifth Annual Cell Surgical World Conference

SUNRISE, FL – June 1, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will be presenting at the Fifth Annual Cell Surgical World Conference in Beverly Hills this Saturday, June 2.

Dr. Comella is, to the Company’s best knowledge, one of the most published scientists in the clinical use of fat derived autologous stem cells.  Her work in the application of autologous (a patient’s own) stem cell therapy is unparalleled, and includes autoimmune, neurodegenerative, orthopedic and degenerative conditions.  To date, the company has worked with more than 10,000 patients and trained more than 700+ physicians worldwide.

The conference, which is hosted by the International Cell Surgical Society, features three different tracks to fit interest levels and backgrounds of all types and includes hands-on training and certification in the practice of autologous stem cell therapy. The Science Only, Physician Practicum, and Physician Practicum Plus Mini-Liposuction Certification and Training tracks provides doctors from around the world access to two days of science in lecture format; a Friday night and Saturday night social cocktail and charity dinner gala at the iconic Beverly Hilton Hotel.

To learn more about ICSS, please visit: http://internationalcellsurgicalsociety.org/

“The privilege of presenting at this conference is monumental, because it’s an opportunity to connect with regenerative-minded physicians from all over the world,” said Dr. Comella.  “I look forward to connecting with these leaders in autologous stem cell therapy and having the opportunity to share information about the remarkable results we are seeing on a regular basis.”

U.S. Stem Cell, Inc., and Dr. Kristin Comella, have taken a leadership role worldwide in the development of adipose-derived, autologous stem cell therapy.  In addition to serving as the Chief Science Officer, Dr. Comella is also President of the Academy of Regenerative Practices and is a leading voice in recognizing the power of regenerative medicine.

Along with the 700+ physicians and clinicians she has trained, she and USRM also have a presence with 287+ clinics around the world — many of which feature clinicians that are trained and certified in stem cell therapy by Dr. Comella and her team.

Autologous stem cell treatments are possible because of stem cells harvested from the patient’s own fat. Their application may offer less invasive alternatives to the use of pharmaceuticals and surgery for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Scientist Talks Stem Cell Journey, Autologous Stem Cells with ‘Something Significant’ Happy Living Podcast

SUNRISE, FL – May 17, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, is featured in the ‘Something Significant’ Happy Living podcast with former NFL player Matt Gersper, where she discusses the inception of her work more than 19 years ago and how she and USRM’s development of novel, therapeutic adipose (fat derived) stem cell treatments, is changing lives. The interview is available for complementary playback here.

Dr. Comella, a world renowned expert in the development and clinical application of autologous stem cell products and therapies, is one voice in a growing movement recognizing the power of regenerative medicine and, in particular, autologous stem cell therapy. Last month, Dr. Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year. She is frequently published in the scientific literature on the practical application of autologous stem cells for regenerative medicine.  

Matt Gersper is the founder of Happy Living and author of The Belief Road Map & Turning Inspiration Into Action.  He is a graduate of U.C. Davis and a former football player for the Canadian, USFL and NFL football leagues. During the past few years, he shifted his business to researching and sharing best practices for happy living with the world.  His mission is to inspire others to live their best self.

As more and more Americans are beginning to discover the opportunity to use their own stem cells for healing, demand for information about her work has been increasing.  Recently, she was featured in the Jeff Hays’ documentary, “The Healing Miracle (available for listen here) ;” a featured guest for the Biohacker Center in Helsinki, Finland (available in its entirety here), and a featured guest on Health Boot Camps’ “The Fountain of Health Has Been Found: An Interview with Dr. Kristin Comella,” (now available on podcast here).

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

SUNRISE, FL – May 15, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science Officer Dr. Kristin Comella’s interview with Ben Pakulski — a world bodybuilding expert who last year received autologous stem cell therapy that successfully treated torn muscles.  Listen to the interview here, or at https://www.benpakulski.com/comella.

Dr. Comella, a world renowned expert in the development and clinical application of autologous stem cell products and therapies, is one voice in a growing movement recognizing the power of regenerative medicine and, in particular, autologous stem cell therapy. Last month, Dr. Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year.

Dr. Comella is frequently published in the scientific literature on the practical application of autologous stem cells for regenerative medicine.  Her work is currently under review by the FDA, who last week announced a lawsuit against USRM’s clinic which would prevent Americans from having access to their own stem cells and would instead require them to classify their own stem cells as a drug.  USRM and its affiliates have vowed to defend the rights of its clients and the practice of regenerative stem cell therapy and its applications.

USRM’s leadership in adipose-derived, autologous stem cell therapy continues to inspire other organizations and physicians — 700+ clinicians and 287+ clinics — many of whom train and certify in stem cell therapy with Dr. Comella and her team, virtually or in person, at U.S. Stem Cell Clinic in Sunrise, Florida. She and her team continue to identify healing opportunities for the application of autologous stem cells in neurological, autoimmune, orthopedic and degenerative conditions.

Autologous stem cell treatments are possible because of stem cells harvested from the patient’s own fat. Their application may offer less invasive alternatives to the use of pharmaceuticals and surgery for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, without the potential risks of rejection or unknown exposure from donated stem cells.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Autologous Stem Cell Therapy May Hold Key to Regeneration

USRM Chief Science Officer’s Live Webinar Adds Voice to Debate

SUNRISE, FL – May 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced the release of USRM Chief Science Officer Dr. Kristin Comella’s Stem Cell 101 Webinar from last Friday, now available for complimentary playback via live link, http://www.brainshark.com/Stemlogix/vu?pi=zGWzp5LSBz5OLvz0.

Dr. Comella, a world renowned expert in the development and clinical application of autologous stem cell products and therapies, is one voice in a growing movement recognizing the power of regenerative medicine and, in particular, autologous stem cell therapy. Last month, Dr. Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year.

Dr. Comella is frequently published in the scientific literature on the practical application of autologous stem cells for regenerative medicine.  Her work is currently under review by the FDA, who last week announced a lawsuit against USRM’s clinic which would prevent Americans’ from having access to their own stem cells and would instead require them to classify their own stem cells as a drug.  USRM and its affiliates have vowed to defend the rights of its clients and the practice of regenerative stem cell therapy and its applications.

USRM’s leadership in adipose-derived, autologous stem cell therapy continues to inspire other organizations and physicians — 700+ clinicians and 287+ clinics — many of whom train and certify in stem cell therapy with Dr. Comella and her team, virtually or in person, at U.S. Stem Cell Clinic in Sunrise, Florida.

Autologous stem cell treatments are possible because of stem cells harvested from the patient’s own fat. Their application may offer less invasive alternatives to the use of pharmaceuticals and surgery for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, without the risks of rejection or unknown exposure from donated stem cells.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

 ###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

USRM Chief Science Officer, Dr. Kristin Comella, to be featured on Health Boot Camps Webinar

Sunrise, FL – May 10, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced its Chief Science Officer, Dr. Kristin Comella, is a featured guest on Health Boot Camps’ “The Fountain of Health Has Been Found: An Interview with Dr. Kristin Comella,” now available on podcast here.

“The consumer demand for sound science and information about autologous stem cell therapy is exploding,” said Dr. Comella, who is a world renowned expert with 20+ years’ experience in the development and clinical practice of stem cell products and therapies.  “It’s great to see the world waking up to how much benefit they can gain by utilizing their bodies’ own healing stem cells, and it is a privilege to help lead the way.”

Dr. Comella is extensively published in the scientific literature in the practical application of autologous stem cell therapy.  Last month, she and her team were the first in the world to publish in-human results in scientific literature of adipose stem cell therapy significantly reducing psoriasis — a condition that affects 7 million plus Americans annually.

Her leadership continues to inspire other physicians who not only refer to her published work, but also can train and certify in stem cell therapy with Dr. Comella and her team.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is a proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat tissue, which are harvested and reinserted in a minimally invasive, two-hour procedure that does not require general anesthesia. Using one’s own, autologous stem cells, may be a significant advantage since it eliminates the risks of rejection or unknown exposure from donated stem cells.  To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to study the use autologous stem cell therapy for their own practices.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

USRM Will Vigorously Defend Medical Freedom of Americans

SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its intention to vigorously defend a lawsuit filed today by the U.S. Department of Justice at the request of the U.S. Food and Drug Administration (FDA).  The lawsuit seeks to stop US Stem Cell Clinic and related parties from performing a surgical procedure using stem cells from autologous adipose tissue, even when a physician and patient agree that such a procedure is in the best interest of the patient. USRM believes that the patient and physician have the right to decide whether or not to use a patient’s own cells for a therapeutic purpose without federal government interference.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead, developmental product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  

#  # #  

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

U.S. Stem Cell Reports First Quarter Results

SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced first quarter results for 2018.

Revenue increased 48%, to $1.7m from $1.15m for the first quarter of 2017.  Gross profit increased more than 52%, to $1.2m from $793k for the same period last year.  Profit margin and net cash flow from operations also increased, from 55% to 71%, and $268k to $688k, respectively.

Working capital deficit is down 11%, from $5.4m at year end 2017 to $4.8m at the end of the first quarter of this year.

For two consecutive years, USRM has sustained substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

“Our first quarter financials reflect a continued increase in market demand, as we continue to manage growth and identify ways to serve the marketplace and our business partners,” said Mike Tomas, President and Chief Executive Officer of U.S. Stem Cell, Inc.  “This is our eighth consecutive quarter of increased revenue — an indication of a possible sea change in how Americans view autologous stem cell therapy, as more and more patients seek alternatives to surgery and pharmaceuticals.”

“Our productivity continues to increase as we further our mission to help educate the public on the value of stem cell therapy, while simultaneously continuing to serve a population that is sick and tired of being sick,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc.  “Helping patients repurpose their own healing cells to employ them where their bodies need them is one of the most important scientific and holistic breakthroughs we have seen in the 21st century. We continue to be dedicated to the application of this incredible therapy to help as many people as possible.”

USRM has been instrumental in administering more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

Dr. Kristin Comella, USRM’s Chief Science Officer, continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary AdipocellTM kit to market.  Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.


U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More